Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia

Experimental Neurology

Volumn 204, Issue 1, 2007, Pages 433-442

  Weng, Yuan Cheng ^a   Kriz, Jasna ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Caspase 3; Inflammation; Mice; Microglia; Middle cerebral artery occlusion

Indexed keywords

CASPASE 3; MINOCYCLINE; NIMODIPINE; RILUZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN TISSUE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROPHAGE; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CASPASE 3; DRUG COMBINATIONS; ENZYME ACTIVATION; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; ISCHEMIC ATTACK, TRANSIENT; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MINOCYCLINE; MYOCARDIAL INFARCTION; NEUROPROTECTIVE AGENTS; NIMODIPINE; RILUZOLE; TIME FACTORS;

EID: 33847326193     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.12.003     Document Type: Article

References (38)

1. Arvin K.L., Han B.H., Du Y., Lin S.Z., Paul S.M., and Holtzman D.M. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann. Neurol. 52 (2002) 54-61
2. Bae H.J., Lee Y.S., Kang D.W., Koo J.S., Yoon B.W., and Roh J.K. Neuroprotective effect of low dose riluzole in gerbil model of transient global ischemia. Neurosci. Lett. 294 (2000) 29-32
3. Baeulieu J.M., Kriz J., and Julien J.P. Induction of peripherin expression in subsets of brain neurons after lesion injury or cerebral ischemia. Brain Res. 946 (2002) 153-161
4. Belayev L., Busto R., Zhao W., Fernandez G., and Ginsberg M.D. Middle cerebral artery occlusion in the mouse by intraluminal suture coated with poly-l-lysine: neurological and histological validation. Brain Res. 833 (1999) 181-190
5. Benchoua A., Braudeau J., Reis A., Couriaud C., and Onteniente B. Activation of proinflammatory caspases by cathepsin B in focal cerebral ischemia. J. Cereb Blood Flow Metab. 24 (2004) 1272-1279
6. Blum D., Chtarto A., Tenenbaum L., Brotchi J., and Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis. 17 (2004) 359-366
7. Chen M., Ona V.O., Li M., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6 (2000) 797-801
8. Choi D. Stroke. Neurobiol. Dis. 7 (2000) 552-558
9. Dirnagl U., Iadecola C., and Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22 (1999) 391-397
10. Elewa H.F., Hilali H., Hess D.C., Machado L.S., and Fagan S.C. Minocycline for short-term neuroprotection. Pharmacotherapy 26 (2006) 515-521
11. Gladstone D.J., Black S.E., and Hakim A.M. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33 (2002) 2123-2136
12. Goulden V., Glass D., and Cunliffe W.J. Safety of long-term high-dose minocycline in the treatment of acne. Br. J. Dermatol. 134 (1996) 693-695
13. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 33 (2001) 306-307
14. Hacke W., Ringleb P., and Stingele R. Thrombolysis in acute ischemic stroke: indications and limitations. Thromb. Haemostasis 82 (1999) 983-986
15. Horn J., deHaan R.J., Vermeulen M., Luiten P.G., and Limburg M. Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke 32 (2001) 2433-2438
16. Hoyte L., Barber P.A., Buchan A.M., and Hill M.D. The rise and fall of NMDA antagonists for ischemic stroke. Curr. Mol. Med. 4 (2004) 131-136
17. Koistinaho M., Malm T.M., Kettunen M.I., Goldsteins G., Starckx S., Kauppinen R.A., Opdenakker G., and Koistinaho J. Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J. Cereb Blood Flow Metab. 25 (2005) 460-467
18. Korenkov A.I., Pahnke J., Frei K., et al. Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg. Rev. 23 (2000) 145-150
19. Kriz J., Nguyen M.D., and Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 10 (2002) 268-278
20. Kriz J., Gowing G., and Julien J.P. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. 53 (2003) 429-436
21. Kriz J., Zupan G., and Simonic A. Differential effects of dihydropyridine calcium channel blockers in kainic acid-induced experimental seizures in rats. Epilepsy Res. 52 (2003) 215-225
22. Krupinski J., Lopez E., Marti E., and Ferrer I. Expression of caspases and their substrates in the rat model of focal cerebral ischemia. Neurobiol. Dis. 7 (2000) 332-342
23. Lo E.H., Dalkara T., and Moskowitz M.A. Mechanisms, challenges and opportunities in stroke. Nat. Rev., Neurosci. 4 (2003) 399-3415
24. Lyden P.D., Jackson-Friedman C., Shin C., and Hassid S. Synergistic combinatorial stroke therapy: a quantal bioassay of a GABA agonist and a glutamate antagonist. Exp. Neurol. 163 (2000) 477-489
25. Ma J., Endres M., and Moskowitz M.A. Synergistic effects of caspase inhibitors and MK-801 in brain injury after transient focal cerebral ischaemia in mice. Br. J. Pharmacol. 124 (1998) 756-762
26. Martin D., Thompson M.A., and Nadler J.V. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol. 250 (1993) 473-476
27. McColl B.W., Carswell H.V., McCulloch J., and Horsburgh K. Extension of cerebral hypoperfusion and ischaemic pathology beyond MCA territory after intraluminal filament occlusion in C57Bl/6J mice. Brain Res. 997 (2004) 15-23
28. Meisel C., Prass K., Braun J., Victorov I., Wolf T., Megow D., Halle E., Volk H.D., Dirnagl U., and Meisel A. Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke. Stroke 35 (2004) 2-6
29. Onal M.Z., Li F., Tatlisumak T., Locke K.W., Sandage Jr. B.W., and Fisher M. Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia in rats. Stroke 28 (1997) 1060-1065
30. Pratt J., Rataud J., Bardot F., Roux M., Blanchard J.C., Laduron P.M., and Stutzmann J.M. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci. Lett. 140 (1992) 225-230
31. Rogers D.C., Fisher E.M., Brown S.D., Peters J., Hunter A.J., and Martin J.E. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm. Genome 8 (1997) 711-713
32. Sathasivam S., Grierson A.J., and Shaw P. Characterization of the caspase cascade in a cell culture model of SOD1-related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition. Neuropathol. Appl. Neurobiol. 5 (2005) 467-485
33. Stoll G., Jander S., and Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol. 56 (1998) 149-171
34. Tikka T., Fiebich B.L., Goldsteins G., Keinanen R., and Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 21 (2001) 2580-2588
35. Wang C.X., Yang T., and Shuaib A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res. 963 (2003) 327-329
36. Yong V.W., Wells J., Giuliani F., Casha S., Power C., and Metz L.M. The promise of minocycline in neurology. Lancet Neurol. 3 (2004) 744-751
37. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., and Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15769-15774
38. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., and Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13496-13500